secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2023-04-17T23:59:59+00:00
Accession:  0001213900-23-030323
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar cuts SF workforce 60%, extends cash runway to mid-2026; CFO departs
--------------------------------------------------------------------------

- Workforce reduction of ~60% in San Francisco; ~55 employees expected post-restructuring.
- Cash, cash equivalents, and marketable securities of ~$456M as of March 31, 2023.
- Restructuring costs ~$8M in Q2 2023; annual savings of ~$30M expected from headcount reduction.
- CFO Jillian Thomsen stepping down; Sandra Gardiner of FLG Partners appointed interim CFO.
- Pipeline focus on immunology (REZPEG) and NKTR-255; seeks partner for NKTR-255.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390023030323/0001213900-23-030323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390023030323/ea177029-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-030323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer